FDA-approved Therapies for Geographic Atrophy

Opinion
Video

An expert retina specialist discusses the recent FDA-approved treatments for geographic atrophy (GA) that slow disease progression and highlights key factors to consider before starting treatment.

Recent Videos
2 experts are featured in this series.
Related Content
Investigators highlight the risk of misdiagnosing geographic atrophy

Investigators highlight the risk of misdiagnosing geographic atrophy

Lynda Charters
March 20th 2025
Article
Spotlighting telemedicine in the year of a pandemic

Spotlighting telemedicine in the year of a pandemic

Alex Delaney-Gesing
October 19th 2020
Podcast
EMA provides positive ATMP opinion for gene therapy products OCU410 and OCU410ST

EMA provides positive ATMP opinion for gene therapy products OCU410 and OCU410ST

Hattie Hayes
March 5th 2025
Article
CDR-Life completes fifth milestone and is recruiting patients for Phase 2 study of BI 771716

CDR-Life completes fifth milestone and is recruiting patients for Phase 2 study of BI 771716

Sydney M Crago
March 2nd 2025
Article
Cognition Therapeutics announces manuscript publication on oral drug candidate zervimesine (CT1812) for treatment of dry AMD

Cognition Therapeutics announces manuscript publication on oral drug candidate zervimesine (CT1812) for treatment of dry AMD

Jordana Joy
March 1st 2025
Article
Ocugen, Inc. completes dosing in Phase 2 portion of ArMaDa clinical trial for OCU410

Ocugen, Inc. completes dosing in Phase 2 portion of ArMaDa clinical trial for OCU410

Sydney M Crago
February 19th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.